More Encouraging Data For Moderna And Merck & Co’s Personalized Cancer Therapy

A therapy individualized to each patient’s cancer has produced encouraging three-year data – though talk of accelerated approval remains a moot point.

Merck 1200

Confidence in Moderna and Merck & Co.'s novel individualized neoantigen therapy (INT) combination with Keytruda has grown after the companies unveiled new three-year data in melanoma patients.

The candidate mRNA-4157 (V940) is a potential first-in-class INT which is important for Merck as it looks to extend its...

More from Business

More from Scrip

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.